WS09.05 Exploring sputum and skin secretion metabolomics for biomarkers of Pseudomonas aeruginosa infection in cystic fibrosis
S. Hadjisymeou Andreou(Royal Brompton Hospital), Jane C. Davies(Guy's and St Thomas' NHS Foundation Trust), James S. McKenzie(Imperial College London), Emmanuelle Bardin(Inserm), Zoltán Takáts(Imperial College London), Amanda Jones(Royal Brompton Hospital)
Cited by 0
Related Papers
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
Metabolic phenotyping in clinical and surgical environments
|Nature|2012|541
<i>Pseudomonas aeruginosa</i>infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches
|Expert Review of Respiratory Medicine|2016|170
Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis
|FEMS Microbiology Letters|2017|107
The<i>Staphylococcus aureus</i>Network Adaptive Platform Trial Protocol: New Tools for an Old Foe
|Clinical Infectious Diseases|2022|98